Participant flow

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia · Source last updated 2022-05-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles ABT199: Oral BCL-2 antagonist

   id

   FG000

   title

   ABT199

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Disease Progression

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Inability to Swallow pills

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Non-compliance

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Lack of Efficacy

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Medical insurance coverage

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   7. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      IgM Myeloma diagnosis

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         33

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         21

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         12

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice